GLP-1s marked first an innovation in diabetes treatment, then a breakthrough in weight loss. Now the drug class continues to reveal more benefits as researchers study its impact on diabetes sufferers’ overall health. Now researchers are again innovating transformative methods and therapies for metabolic diseases.

This trend report examines metabolic disease treatment and research and the breakthroughs that are creating a new future for people living with diabetes and related health concerns

In this Industry Pulse report, we’ll discuss:

• What biotech startups need to do to manage the high patient demand for compounded GLP-1 alternatives and their exposure to liability and underwriting. 
• Examining the early data and promising potential of GLP-1 medications in warding off venous thromboembolism (VTE).
• How the next wave in diabetes treatment may be in a groundbreaking single-cell therapy.
• How adaptive trial methodology maximizes the chance of benefit for both researchers and patients.

​